TY - JOUR
TI - IGF-1, IGFBP-3 and breast cancer risk in women: The European Prospective
Investigation into Cancer and Nutrition (EPIC)
AU - Rinaldi, S.
AU - Peeters, P. H. M.
AU - Berrino, F.
AU - Dossus, L. and
AU - Biessy, C.
AU - Olsen, A.
AU - Tjonneland, A.
AU - Overvad, K. and
AU - Clavel-Chapelon, F.
AU - Boutron-Ruault, M. C.
AU - Tehard, B.
AU - Nagel,
AU - G.
AU - Linseisen, J.
AU - Boeing, H.
AU - Lahmann, P. H.
AU - Trichopoulou,
AU - A.
AU - Trichopoulos, D.
AU - Koliva, M.
AU - Palli, D.
AU - Panico, S. and
AU - Tumino, R.
AU - Sacerdote, C.
AU - van Gils, C. H.
AU - van Noord, P. and
AU - Grobbee, D. E.
AU - Bueno-de-Mesquita, H. B.
AU - Gonzalez, C. A. and
AU - Agudo, A.
AU - Chirlaque, M. D.
AU - Barricarte, A.
AU - Larranaga, N. and
AU - Quiros, J. R.
AU - Bingham, S.
AU - Khaw, K. T.
AU - Key, T.
AU - Allen, N.
AU - E.
AU - Lukanova, A.
AU - Slimani, N.
AU - Saracci, R.
AU - Riboli, E. and
AU - Kaaks, R.
JO - Endocrine-Related Cancer
PY - 2006
VL - 13
TODO - 2
SP - 593-605
PB - BioScientifica Ltd
SN - 1351-0088, 1479-6821
TODO - 10.1677/erc.1.01150
TODO - null
TODO - Blood concentrations of insulin-like growth factor-I (IGF-I) and
insulin-like growth factor binding protein-3 (IGFBP-3) have recently
been associated with breast cancer risk, notably in women who developed
breast cancer at a young age. Prospective studies published so far,
however, were relatively small and odds ratio (OR) estimates imprecise.
We present the results of a large prospective case-control study nested
within the European Prospective Investigation into Cancer and Nutrition
on total IGIF-I, IGFBP-3 and breast cancer risk including 1081 incident
cases of invasive breast cancer and 2098 matched control subjects.
Increasing IGF-I and IGFBP-3 concentrations were associated with a
significant increase in breast cancer risk in women who developed breast
cancer after 50 years of age (highest vs lowest quintile OR 1.38 (95%
confidence interval (CI) 1.02-1.86), P = 0.01, and 1.44 (95% CI
1.04-1.98), P = 0.01, respectively), but no relationship was observed in
younger women (OR = 1.03 (95% CI 0.60-1.77), P = 0.81 for IGF-I, and OR
= 0.92 (95% CI 0.50-1.70), P = 0.69 for IGFBP-3). There was, however,
significant heterogeneity in the relationship of breast cancer with
serum IGF-I and IGFBP-3 levels depending on the time interval between
blood donation and tumor diagnosis. A reduction in breast cancer risk
with increasing IGF-I concentrations was observed in cases with a
diagnosis of cancer less than 2 years after blood donation, (OR = 0.76
(95% CI 0.57-1.03)), while an increase in risk was observed for women
with a later diagnosis (above or equal to two years after blood
collection, OR = 1.51 (95% CI 1.19-1.91)). A similar pattern was
observed for IGFBP-3. This study confirms previous findings for an
association of serum IGF-I and IGFBP-3 concentrations with breast cancer
risk, particularly for women with a later diagnosis of cancer, but it
does not support the hypothesis of an involvement of IGF-I in younger
women.
ER -